Girl dies from food poisoning, 7 others sickened after eating meat from butcher shops in France
Two butcher shops in northern France have temporarily closed after a child died from severe food poisoning, said local authorities on Friday.
Eight children have come down with severe food poisoning since June 12 after consuming meat products from the two businesses in the northern city of Saint-Quentin.
Five of them contracted a rare foodborne illness called hemolytic uremic syndrome (HUS), including a 12-year-old girl who died.
HUS in most cases occurs after someone ingests E.coli, commonly found in the gut of humans and warm-blooded animals. HUS can lead to kidney failure, permanent health problems and even death, according to the Centers for Disease Control and Prevention.
It is "impossible at this stage to confirm that the consumption of products from these two establishments is the source of the contamination," local authorities said.
But the children all consumed meat or meat products from these two butchers a few days before symptoms appeared, it said.
Authorities have closed the two shops as a precautionary measure while samples from both stores are tested.
The authorities said they should have the results "early next week" and an investigation has been launched into where the meat came from.
HUS affects between 100 and 165 children in France each year, according to the country's public health agency.
E. coli outbreaks have also made headlines recently in the U.S. Earlier this month, the Department of Agriculture's Food Safety and Inspection Service announced that ground beef that was distributed nationwide may be contaminated with E. coli.
In November, a carrot recall was issued by California grower Grimmway Farms after nearly 40 cases were recorded in 18 states. At least 15 people were hospitalized and one person died, the CDC said.
The month before that, an outbreak linked to McDonald's Quarter Pounders killed one person in Colorado and affected at least 104 people across 14 states, according to the CDC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
25 minutes ago
- New York Times
With Flu Shot Vote, Kennedy's Vaccine Skepticism Comes Full Circle
A decade before he became President Trump's health secretary, the environmental lawyer Robert F. Kennedy Jr. appeared on a talk show hosted by Dr. Mehmet Oz to promote his latest book, 'Thimerosal: Let the Science Speak.' The book, published in 2014, explored an obscure mercury-based preservative, thimerosal, that was removed from most vaccines, but not flu vaccines, more than two decades ago. Dr. Oz noted that the Centers for Disease Control and Prevention had deemed the vaccines that still contained thimerosal 'safe and effective' and said they did 'not present a public health risk.' Mr. Kennedy did not buy it. 'We found 500 peer-reviewed studies,' he insisted. 'Virtually every one of them said that thimerosal is a potent neurotoxin that should not be in vaccines.' On Thursday, the new members of the C.D.C.'s Advisory Committee on Immunization Practices, hand-selected by Mr. Kennedy after he fired all 17 members of the previous panel, decided it would longer recommend annual flu shots that contain it. Thimerosal's appearance on the committee's agenda in the first place shocked public health leaders, who have long considered the matter settled. But it was not a surprise to people who have followed Mr. Kennedy closely. Thimerosal started Mr. Kennedy down a path of questioning vaccine safety, and Thursday's vote was the culmination of a long personal journey. It offers a window into how, as secretary, he is pursuing his own passions and installing old allies in positions of influence. Want all of The Times? Subscribe.
Medscape
an hour ago
- Medscape
New Data at EULAR Signal Advances in RA, Myopathy, Gout
Barcelona has become the world capital of rheumatology by hosting the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology (EULAR) in Spain. 'This is the world's largest rheumatology event,' said Daniel Aletaha, MD, president of EULAR and head of the Department of Rheumatology at the University Clinic for Internal Medicine III, MedUni Vienna, Vienna, Austria, during the conference opening session. He highlighted the scale of participation: 5125 abstracts submitted from 95 countries, 117 sessions, and 350 speakers from 45 nations. Inflammatory and Autoimmune Disease Among the plenary highlights was research led by Jason D. Turner, PhD, a postdoctoral research fellow at the University of Birmingham, Birmingham, England. His comparative analysis of synovial tissue using single-cell and spatial transcriptomics identified overlapping disease pathways in spontaneous inflammatory arthritis and arthritis induced by immune checkpoint inhibitors. 'We found that the synovium in checkpoint inhibitor-associated arthritis is enriched with fibroblasts and T cells, is highly vascularised, and contains large numbers of CXCL9/10/11+ macrophages and CD8+ T cells. These findings support the current use of tumour necrosis factor inhibitors for this condition, although further investigation is needed to understand their applicability to spontaneous arthritis,' Turner explained. Hector Chinoy, PhD, FRCP, professor of rheumatology at the University of Manchester and lead at the Salford Royal Adult Neuromuscular Service, Manchester, England, presented the results of the ALKIVIA phase 2 study. This trial evaluated the efficacy of subcutaneous efgartigimod (PH20) administration in adults with active idiopathic inflammatory myopathy. The drug led to significant improvements in the Total Improvement Score compared with placebo and showed good tolerability and safety. 'These findings demonstrate the mechanistic importance of neonatal Fc receptor inhibition and suggest a potential pathogenic role for autoantibodies. These findings support the continued evaluation of the drug in the ongoing phase 3 trial' Chinoy said. Scleroderma, Preclinical Rheumatoid Arthritis (RA), Gout, and Lupus Adela‑Cristina Sarbu, MD, a researcher specialising in systemic sclerosis and interstitial lung disease at the University Hospital Bern, Bern, European Scleroderma Trials and Research group (EUSTAR), and the University of Zurich, Zurich, Switzerland, presented the findings from the EUSTAR cohort. In conclusion, exposure to prostanoids appeared to be associated with a slower progression of interstitial lung disease in patients with mild vascular disease. In contrast, exposure to endothelin receptor antagonists appeared to be beneficial in preventing symptom worsening in patients with more severe vascular diseases. 'No independent mortality benefit was seen with vasoactive or vasodilator drugs. Their effectiveness seems to depend on the severity of vascular disease' Sarbu noted, calling for further long-term studies. The ALTO study, an extension of the APIPPRA trial, led by Andrew Cope, PhD, of King's College London, London, England, found that a 1-year course of abatacept in individuals at high risk of developing RA could delay disease onset by up to 4 years. 'Individuals with baseline autoantibody profiles are more likely to develop the disease and respond well to T-cell co-stimulation blockade. Abatacept reduces the symptom burden during treatment but does not provide sustained benefits after treatment discontinuation. No new safety concerns were reported,' according to Cope. Edoardo Cipolletta, MD, rheumatologist at the Marche University Hospital, Ancona, Italy, and research associate at the University of Nottingham, Nottingham, England, presented an analysis of data on primary care, hospitalization, and mortality outcomes related to gout, based on cohorts from the UK and Sweden. The study found that achieving serum urate levels below 360 µmol/L within a year of initiating urate-lowering treatment was associated with a significantly lower risk for major adverse cardiovascular events. The 5-year relative risk reduction ranged from 6% to 11%, with an absolute survival benefit of 1.3%-1.4%. 'The association was consistent regardless of prior cardiovascular disease and across all sensitivity analyses,' Cipolletta reported. Richard A. Furie, MD, chief of Rheumatology at Northwell Health in New York, presented results from the REGENCY study, which evaluated obinutuzumab in patients with lupus nephritis. Award Recognition Miriam Ruiz Ponce, MSc, a predoctoral researcher at the Maimonides Biomedical Research Institute in Córdoba, Spain received one of the EULAR award for translational basic science. She developed a mouse model of fatty liver disease associated with inflammatory arthritis to evaluate the anti-inflammatory and metabolic properties of apremilast, a drug commonly used in psoriatic arthritis. 'Early results have shown that the drug has promising effects, as it partially reverses liver damage, as well as inflammation. These are the initial results, but it could be a potential treatment for inflammation and for the deleterious effects on the liver in these patients. It is an honour to receive this award, which motivates us to continue our research under the leadership of my mentor, Nuria Barbarroja Puerto, PhD, the principal investigator of the potential treatment targeting inflammation and liver damage,' she said. Chinoy disclosed financial relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Furie disclosed the financial relationships with GSK and Genentech; the REGENCY study was funded by F. Hoffmann-La Roche. Sarbu and Cope disclosed having no relevant financial relationships. Turner, Cipolletta, and Ponce did not provide conflict-of-interest disclosures.
Yahoo
2 hours ago
- Yahoo
Protecting children online: The time to act is now
In today's digital era, children are growing up in a world where social media are as integral to their daily lives as school or family. While technology offers tremendous opportunities for learning, creativity, and connection, it also exposes young people to significant risks that can no longer be overlooked. The consequences are deeply concerning. According to a 2023 report by the European Commission, one in three young people in the EU spends more than three hours per day on social media. This level of overexposure has been closely associated with a growing mental health issues among minors—including anxiety, depression, and low self-esteem. A 2024 study by the World Health Organisation showed that a problematic social media use among adolescents increased from 7% in 2018 to 11% in 2022. It highlights negative impacts on mental health, sleep, well-being and academic performance. Social media platforms – often built around addictive algorithms – are designed to keep young users engaged for extended periods. Constant exposure to idealised, curated content can distort self-perception, fuelling feelings of inadequacy and dissatisfaction. These are not just statistics—they reflect the genuine emotional and psychological struggles faced by an entire generation that is increasingly ill–equipped to navigate the digital world in a healthy and balanced manner. Europe has made notable progress through initiatives like the Better Internet for Kids (BIK+) strategy and the Digital Services Act (DSA). Yet, the current framework remains insufficient. The online protection of children must be elevated to a political and societal priority, underpinned by concrete and enforceable action. We must therefore move swiftly to implement a set of focused measures, starting with default privacy settings for children's accounts to reduce the risk of unsolicited contact from strangers. We also asking for ecalibrated recommender systems that prioritise explicit user feedback—such as deliberate selection of topics—to minimise the risk of children being drawn into harmful content rabbit holes. We want enhanced safety controls, including the ability for children to block or mute any user and protection from being added to group chats without their explicit consent, thereby reducing exposure to cyberbullying. Above all, mandatory age verification mechanisms must be implemented across all social networks. Such measures are essential to prevent minors from bypassing age restrictions and to substantially reduce their exposure to harmful online environments. The European Commission's recent draft guidelines on the protection of minors under the DSA mark a significant step towards a safer digital space. They offer a unique opportunity to establish age verification a a standard practice across social networks—not as an optional feature, but as a strict requirement. Enforcing age verification will equip platforms with the technical means necessary to uphold their own terms of service. It will also facilitate the enforcement of EU and national laws that set minimum age requirements for access to specific digital products or services. If we are genuinely committed to ensuring that the digital world fosters healthy development, learning, and meaningful connection—rather than becoming a breeding ground for anxiety, addiction and harm—then the decisive action must be taken now. Alexander Pröll, State Secretary for Digitalisation, Combating Antisemitism and Public Service, and the Constitution, Austria; Prof Radovan Fuchs, PhD., Minister of Science, Education and Youth, Croatia; Damir Habijan, Minister of Justice, Public Administration and Digital Transformation, Croatia; Dr Nicodemos Damianou, Deputy Minister of Research, Innovation and Digital Policy, Cyprus; Caroline Stage Olsen, Minister for Digital Affairs, Denmark; Clara Chappaz, Minister of Artificial intelligence and Digital Affairs, France; Elisabeth Borne, Minister of National Education, Higher Education and Research, France; Catherine Vautrin, Minister of Labour, Health, Solidarity, and Families, France; Karin Prien, Federal Minister of Education, Family Affairs, Senior Citizens, Women and Youth, Germany; Dimitrios Papastergiou, Minister of Digital Governance, Greece; Sofia Zacharaki, Minister of Education, Religious Affairs and Sports, Greece; Patrick O'Donovan, Minister for culture and communications, Ireland; Prof Giuseppe Valditar, Minister for Education and Merit, Italy; Alessio Butti, Undersecretary of State to the Presidency of the Council of Ministers, responsible for technological innovation and digital transition, Italy; Elisabeth Margue, Minister for Justice and Minister attached to the Prime Minister, responsible for the Media and Connectivity, Luxembourg; Claude Meisch, Minister for Education, Children and Youth Affairs, Luxembourg; Tomáš Drucker, Minister of Education, Research, Development, and Youth, Slovakia; Ksenija Klampfer, Minister of Digital Transformation, Slovenia; Vinko Logaj, Minister of Education and Care, Slovenia; Oscar López Águeda, Minister for Digital and Civil Service Transformation, Spain and María del Pilar Alegría Continente, Minister for Education and Vocational Training, Spain all coauthored this opinion article.
